ISAL 2025 | FLT3 mutations in ALL: potential impact on prognosis and treatment approaches
Boaz Nachmias, MD, PhD, Hadassah Medical Center, Jerusalem, Israel, comments on the impact of FLT3 mutations in acute lymphoblastic leukemia (ALL). Dr Nachmias notes that while data is still limited, the study’s findings suggest that FLT-3 inhibition may be an option to consider for patients with FLT-3 mutated ALL at relapse. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The interest in this project was starting in one of my patients with ALL where we detected the FLT3 mutation and that made me wonder what’s the possible implication of that both in terms of prognostic ability similar to AML and also in terms of treatment because sometimes in this patient we are left without treatment options. So we embarked and looked retrospectively in all of our ALL samples and looked for FLT3 mutations, and we actually found a very low rate of mutations, which is resonating well with what is already published...
The interest in this project was starting in one of my patients with ALL where we detected the FLT3 mutation and that made me wonder what’s the possible implication of that both in terms of prognostic ability similar to AML and also in terms of treatment because sometimes in this patient we are left without treatment options. So we embarked and looked retrospectively in all of our ALL samples and looked for FLT3 mutations, and we actually found a very low rate of mutations, which is resonating well with what is already published. So we need a bigger cohort to really understand what’s the possible prognostic implication and whether these patients at relapse can benefit from FLT3 inhibition. So it’s something out there, we need to think about that, especially in the relapse setting, as an option, but data is still lacking in terms of really making clear conclusions.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honoraria: Abbvie.
